Medical Developments International Limited (AU:MVP)
ASX:MVP
Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.55
<AU$0.01(1.18%)
At close: 4:00 PM EST
AU$0.55
<AU$0.01(1.18%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.77
Previous CloseN/A
Volume7.44K
Average Volume (3M)118.82K
Market Cap
AU$47.32M
Enterprise ValueAU$32.09M
Total Cash (Recent Filing)AU$16.88M
Total Debt (Recent Filing)AU$3.34M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding112,658,325
10 Day Avg. Volume79,692
30 Day Avg. Volume118,816
Financial Highlights & Ratios
PEG Ratio-6.86
Price to Book (P/B)1.17
Price to Sales (P/S)1.65
P/FCF Ratio-132.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.85Price Target Upside54.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$42.80M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 75%+ gross margin signals durable unit economics and manufacturing/pricing efficiency. Such margins provide structural buffer against input cost inflation, support sustained commercial and regulatory investment, and enable margin recovery even if operating costs rise over the next 2–6 months.
Low Financial LeverageVery low leverage gives the company financial flexibility and lowers solvency risk. This balance sheet strength supports funding of pediatric approvals, partner transitions, and targeted commercial spend without immediate refinancing pressure, making the business more resilient over the medium term.
Pain Momentum & Regulatory ProgressStrong Pain category growth and published pediatric evidence with impending Europe pediatric approvals expand the addressable market and underpin sustained adoption by hospitals and ambulance trusts. This structural commercial and regulatory progress supports recurring Penthrox volumes and long-term revenue growth.
Bears Say
Weak Cash GenerationSeverely deteriorated free cash flow and negative operating cash flow indicate poor internal funding capacity. This constrains the firm's ability to self-fund medical/commercial rollouts and absorb Respiratory softness, increasing reliance on cash reserves or external funding and elevating medium-term execution risk.
Respiratory Segment DeclineA material and persistent Respiratory sales decline, especially in the U.S., reduces revenue diversification and places greater dependence on Pain revenues. If weakness continues, it will pressure group growth and margins and may require sustained investment or partner strategy shifts to stabilize the segment.
Very Weak Operating ProfitabilityNear-zero EBIT and net margins show the company struggles to convert strong gross margins into operating profits. This limits capacity to reinvest, reduces shareholder return potential, and leaves earnings highly sensitive to FX, pricing, and cost pressures unless margin initiatives deliver measurable improvement.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.77 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$47.32M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Feb 18, 2026. The company reported -AU$0.002 earnings per share for the quarter, beating the consensus estimate of -AU$0.014 by AU$0.012.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is >-0.01.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of -AU$0.002 in its last earnings report, beating expectations of -AU$0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.85 (54.55% Upside)
AU$0.85 (54.55% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
-0.79%
Trailing 12-Months
Asset Growth
-2.70%
Trailing 12-Months
Company Description
Medical Developments International Limited
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$0.85
▲(54.55% Upside)
Technical Analysis
Options Prices
Currently, No data available
---